Estimates of cancer potency of 2,3,4,7,8-Pentachlorodibenzofuran using both nonlinear and linear approaches

Toxicological Sciences

Volumn 106, Issue 2, 2008, Pages 519-537

  Simon, Ted ^a   Kirman, Christopher R ^b   Aylward, Lesa L ^c   Budinsky, Robert A ^d   Rowlands, J Craig ^d   Long, Tom F ^b  

^a Ted Simon LLC   (United States)

^b The Sapphire Group Inc   (United States)

^c LLP   (United States)

^d DOW CHEMICAL COMPANY   (United States)

Author keywords

2,3,4,7,8 pentachlorodibenzofuran; Cancer potency factor; Dose response; Doxin; Reference dose; Tumor promotion

Indexed keywords

2,3,7,8 TETRACHLORODIBENZOFURAN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; BIOASSAY; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; LIVER CELL CARCINOMA; LIVER TOXICITY; NONHUMAN; RAT; RISK ASSESSMENT; SPRAGUE DAWLEY RAT; TISSUE LEVEL; TOXICOKINETICS;

ANIMALS; BENZOFURANS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 56649123528     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn176     Document Type: Article

References (88)

1. Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., and Ingelman-Sundberg, M. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 64(3), 659-669.
2. Andersen, M. E., Mills, J. J., Gargas, M. L., Kedderis, L., Birnbaum, L. S., Neubert, D., and Greenlee, W. F. (1993). Modeling receptor-mediated processes with dioxin: Implications for pharmacokinetics and risk assessment. Risk Anal. 13(1), 25-36.
3. Aylward, L. L., Brunet, R. C., Carrier, G., Hays, S. M., Cushing, C. A., Needham, L. L., Patterson, D. G., Jr., Gerthoux, P. M., Brambilla, P., and Mocarelli, P. (2004). Concentration-dependent TCDD elimination kinetics in humans: Toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. J. Expo. Anal. Environ. Epidemiol. 15, 51-65.
4. Aylward, L. L., Brunet, R. C., Starr, T. B., Carrier, G., Delzell, E., Cheng, H., and Beall, C. (2005). Exposure reconstruction for the TCDD-exposed NIOSH cohort using a concentration- and age-dependent model of elimination. Risk Anal. 25, 945-956.
5. Ayotte, P., Dewailly, E., Lambert, G. H., Perkins, S. L., Poon, R., Feeley, M., Larochelle, C., and Pereg, D. (2005). Biomarker measurements in a coastal fish-eating population environmentally exposed to organochlorines. Environ. Health Perspect. 113(10), 1318-1324.
6. Birnbaum, L. S., and DeVito, M. J. (1995). Use of toxic equivalency factors for risk assessment for dioxins and related compounds. Toxicology 105, 391-401.
7. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P. (1997). Physiological Parameter Values for physiologically-based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484.
8. Budinsky, R. A., Paustenbach, D., Fontaine, D., Landenberger, B., and Starr, T. B. (2006). Recommended relative potency factors for 2,3,4,7, 8-pentachlorodibenzofuran: The impact of different dose metrics. Toxicol. Sci. 91, 275-285.
9. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F. (1989). Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86(20), 7696-7700.
10. Carrier, G., Brunet, R. C., and Brodeur, J. (1995a). Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. I. Nonlinear distribution of PCDD/PCDF body burden between liver and adipose tissues. Toxicol. Appl. Pharmacol. 131, 253-266.
11. Carrier, G., Brunet, R. C., and Brodeur, J. (1995b). Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. II. Kinetics of absorption and disposition of PCDDs/PCDFs. Toxicol. Appl. Pharmacol. 131, 267-276.
12. Chang, J. T., Chang, H., Chen, P. H., Lin, S. L., and Lin, P. (2007). Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin. Cancer Res. 13(1), 38-45.
13. Chao, H. R., Tsou, T. C., Li, L. A., Tsai, F. Y., Wang, Y. F., Tsai, C. H., Chang, E. E., Miao, Z. F., Wu, C. H., and Lee, W. J. (2006). Arsenic inhibits induction of cytochrome P450 1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatoma cells. J. Hazard. Mater. 137(2), 716-722.
14. Chen, H. L., Su, H. J., Wang, Y. J., Guo, Y. L., Liao, P. C., and Lee, C. C. (2006). Interactive effects between CYP1A1 genotypes and environmental polychlorinated dibenzo-p-dioxins and dibenzofurans exposures on liver function profile. J. Toxicol. Environ. Health A 69(3-4), 269-281.
15. Clewell, H. J., III., Andersen, M. E., and Barton, H. A. (2002). A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 110(1), 85-93.
16. Cohen, S. M., Klaunig, J., Meek, M. E., Hill, R. N., Pastoor, T., Lehman-McKeeman, L., Bucher, J., Longfellow, D. G., Seed, J., Dellarco, V., et al. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 78, 181-186.
17. Cole, P., Trichopoulos, D., Pastides, H., Starr, T., and Mandel, J. S. (2003). Dioxin and cancer: A critical review. Regul. Toxicol. Pharmacol. 38, 378-388.
18. Connor, K. T., and Aylward, L. L. (2006). Human response to dioxin: Aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. J. Toxicol. Environ. Health B Crit. Rev. 9, 147-171.
19. Conolly, R. B., and Andersen, M. E. (1997). Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: Evaluation of a quantitative two-cell model and of CYP 1A1/ 1A2 as a dosimeter. Toxicol. Appl. Pharmacol. 146(2), 281-293.
20. Cox, D. R., and Oakes, D. (1984). Analysis of Survival Data. Chapman and Hall, London, New York.
21. Diliberto, J. J., Burgin, D. E., and Birnbaum, L. S. (1999). Effects of CYP1A2 on disposition of 2,3,7, 8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2′,4,4′,5,5′-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice. Toxicol. Appl. Pharmacol. 159, 52-64.
22. Dorne, J. L., and Renwick, A. G. (2005). The refinement of uncertainty/ safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 86, 20-26.
23. Fernby, L. L., Knutsen, J. S., Harris, M., Unice, K. M., Scott, P., Nony, P., Haws, L. C., and Paustenbach, D. (2006). Evaluation of PCDD/F and dioxin-like PCB serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey of the United States population. J. Exp. Sci. Environ. Epidemiol. 17, 358-371.
24. Garabrant, D., Chen, Q., Hong, B., Franzblau, A., Lepkowski, J., Adriaens, P., Demond, A., Hedgeman, E., Knutson, K., Chang, C.-W., et al. (2007a). Logistic regression models for high serum 2,3,7,8-TCDD concentrations in residents of Midland, Michigan, USA. Organohalogen Compd. 69, 2203-2206.
25. Garabrant, D., Hong, B., Chen, Q., Franzblau, A., Lepkowski, J., Adriaens, P., Demond, A., Hedgeman, E., Knutson, K., Zwica, L., et al. (2007b). Factors that predict serum dioxin concentrations in Michigan, USA. Organohalogen Compd. 69, 206-209.
26. Ghotbi, R., Christensen, M., Roh, H. K., Ingelman-Sundberg, M., Aklillu, E., and Bertilsson, L. (2007). Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63(6), 537-546.
27. Graham, M. J., Lucier, G. W., Linko, P., Maronpot, R. R., and Goldstein, J. A. (1988). Increases in cytochrome P-450 mediated 17 beta-estradiol 2-hydroxylase activity in rat liver microsomes after both acute administration and subchronic administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin in a two-stage hepatocarcinogenesis model. Carcinogenesis 9(11), 1935-1941.
28. Gray, M. N., Aylward, L. L., and Keenan, R. E. (2006). Relative cancer potencies of selected dioxin-like compounds on a body-burden basis: Comparison to current toxic equivalency factors (TEFs). J. Toxicol. Environ. Health A 69, 907-917.
29. Hailey, J. R., Walker, N. J., Sells, D. M., Brix, A. E., Jokinen, M. P., and Nyska, A. (2005). Classification of proliferative hepatocellular lesions in Harlan Sprague-Dawley rats chronically exposed to dioxin-like compounds. Toxicol. Pathol. 33, 165-174.
30. Haws, L. C., Su, S. H., Harris, M., DeVito, M. J., Walker, N. J., Farland, W. H., Finley, B., and Bimbaum, L. S. (2006). Development of a refined database of mammalian relative potency estimates for dioxin-like compounds. Toxicol. Sci. 89, 4-30.
31. Holsapple, M. P., Pitot, H. C., Cohen, S. M., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89, 51-56.
32. Iida, T., Hirakawa, H., Matsueda, T., Nagayama, J., and Nagata, T. (1999). Polychlorinated dibenzo-p-dioxins and related compounds: Correlations of levels in human tissues and in blood. Chemosphere 38, 2767-2774.
33. Kirman, C. R., Sweeney, L. M., Meek, M. E., and Gargas, M. L. (2003). Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 38, 345-367.
34. Kitamura, K., Nagahashi, M., Sunaga, M., Watanabe, S., and Nagao, M. (2001). Balance of intake and excretion of 20 congeners of polychlorinated dibenzo-p-dioxin, polychlorinated dibenzofuran and coplanar polychlorinated biphenyl in healthy Japanese men. J. Health Sci. 47, 145-154.
35. Koch, J. P., ten Tusscher, G. W., Koppe, J. G., and Guchelaar, H. J. (1999). Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. Biomed. Chromatogr. 13(4), 309-314.
36. Kociba, R. J., Keyes, D. G., Beyer, J. E., Carreon, R. M., Wade, C. E., Dittenber, D. A., Kalnins, R. P., Frauson, L. E., Park, C. N., Barnard, S. D., et al. (1978). Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 46(2), 279-303.
37. Korashy, H. M., and El-Kadi, A. O. (2008). Modulation of TCDD-mediated induction of cytochrome P450 1A1 by mercury, lead, and copper in human HepG2 cell line. Toxicol. In Vitro 22(1), 154-158.
38. Lambert, G. H., Needham, L. L., Turner, W., Lai, T. J., Patterson, D. G., Jr., and Guo, Y. L. (2006). Induced CYP1A2 activity as a phenotypic biomarker in humans highly exposed to certain PCBs/PCDFs. Environ. Sci. Technol. 40(19), 6176-6180.
39. Maruyama, W., and Aoki, Y. (2006). Estimated cancer risk of dioxins to humans using a bioassay and physiologically based toxicokinetic model. Toxicol. Appl. Pharmacol. 214, 188-198.
40. Maruyama, W., Yoshida, K., Tanaka, T., and Nakanishi, J. (2002). Possible range of dioxin concentration in human tissues: Simulation with a physiologically based model. J. Toxicol. Environ. Health A 65 2053-2073.
41. Masuda, Y. (2001). Fate of PCDF/PCB congeners and change of clinical symptoms in patients with Yusho PCB poisoning for 30 years. Chemosphere 43, 925-930.
42. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33, 591-653.
43. Moser, G. A., and McLachlan, M. S. (2001). The influence of dietary concentration on the absorption and excretion of persistent lipophilic organic pollutants in the human intestinal tract. Chemosphere 45, 201-211.
44. National Academy of Sciences (NAS). (2006). Health Risks from Dioxin and Related Compounds: Evaluation of the EPA Reassessment. Available at: http://www.nap.edu/catalog/11688.html. Accessed January 23, 2008.
45. National Toxicology Program (NTP). (2006a). NTP toxicology and carcinogenesis studies of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS No. 57117-31-4) in female Harlan Sprague-Dawley rats (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 525, 1-198.
46. National Toxicology Program (NTP). (2006b). NTP toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzodioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. NIH Publication No. 04-4455. Peer Reviewed February 17, 2004.
47. Nohara, K., Ao, K., Miyamoto, Y., Ito, T., Suzuki, T., Toyoshiba, H., and Tohyama, C. (2006). Comparison of the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 gene expression profile in lymphocytes from mice, rats, and humans: Most potent induction in humans. Toxicology 225(2-3), 204-213.
48. Pitot, H. C., Goldsworthy, T. L., Moran, S., Kennan, W., Glauert, H. P., Maronpot, R. R., and Campbell, H. A. (1987). A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci. Carcinogenesis 8(10), 1491-1499.
49. Popp, J. A., Crouch, E., and McConnell, E. E. (2006). A weight-of-evidence analysis of the cancer dose-response characteristics of 2,3,7,8-tetrachlorodibenzodioxin (TCDD). Toxicol. Sci. 89 361-369.
50. Randerath, E., Randerath, K., Reddy, R., Narasimhan, T. R., Wang, X., and Safe, S. (1993). Effects of polychlorinated dibenzofurans on compounds in hepatic DNA of female Sprague-Dawley rats: Structure dependence and mechanistic considerations. Chem. Biol. Interact. 88(2-3), 175-190.
51. Randerath, K., Putman, K. L., Randerath, E., Mason, G., Kelley, M., and Safe, S. (1988). Organ-specific effects of long term feeding of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 1,2,3,7,8-pentachlorodibenzo-p-dioxin on I-compounds in hepatic and renal DNA of female Sprague-Dawley rats. Carcinogenesis 9 (12), 2285-2289.
52. Randerath, K., Putman, K. L., Randerath, E., Zacharewski, T., Harris, M., and Safe, S. (1990). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on I-compounds in hepatic DNA of Sprague-Dawley rats: Sex-specific effects and structure-activity relationships. Toxicol. Appl. Pharmacol. 103(2), 271-280.
53. Roberts, E. S., Hopkins, N. E., Foroozesh, M., Alworth, W. L., Halpert, J. R., and Hollenberg, P. F. (1997). Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos. 25 (11), 1242-1248.
54. Roos, P. H., Belik, R., Follmann, W., Degen, G. H., Knopf, H. J., Bolt, H. M., and Golka, K. (2006). Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1 and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments. Arch. Toxicol. 80(1), 45-52.
55. Ruby, M. V., Casteel, S. W., Evans, T. J., Fehling, K. A., Paustenbach, D. J., Budinsky, R. A., Giesy, J. P., Aylward, L. L., and Landenberger, B. D. (2004). Rapid communication: Background concentrations of dioxins, furans and PCBs in Sprague-Dawley rats and Juvenile Swine. J. Toxicol. Environ. Health A 67, 845-850.
56. Ryan, J. J., Gasiewicz, T. A., and Brown, J. F., Jr. (1990). Human body burden of polychlorinated dibenzofurans associated with toxicity based on the Yusho and Yucheng incidents. Fundam. Appl. Toxicol. 15 722-731.
57. Ryan, J. J., Levesque, D., Panopio, L. G., Sun, W. F., Masuda, Y., and Kuroki, H. (1993). Elimination of polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) from human blood in the Yusho and Yu-Cheng rice oil poisonings. Arch. Environ. Contam. Toxicol. 24(4), 504-512.
58. Schrenk, D., Lipp, H.-P., Wiesmuller, T., Hagenmaier, H., and Bock, K. W. (1991). Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins: Comparison between defined mixtures and their constituents. Arch. Toxicol. 65, 114-118.
59. Schrenk, D., Schmitz, H. J., Bohnenberger, S., Wagner, B., and Worner, W. (2004). Tumor promoters as inhibitors of apoptosis in rat hepatocytes. Toxicol. Lett. 149(1-3), 43-50.
60. Schrenk, D., Stilven, T., Gohl, G., Viebahn, R., and Bock, K. W. (1995). Induction of CYP1A and glutathione-S-transferase by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatocyte cultures. Carcinogenesis 16(4), 943-946.
61. Schwarz, M., and Appel, K. E. (2005). Carcinogenic risks of dioxin: Mechanistic considerations. Regul. Toxicol. Pharmacol. 43, 19-34.
62. Seed, J., Carney, E. W., Corley, R. A., Crofton, K. M., DeSesso, J. M., Foster, P. M., Kavlock, R., Kimmel, G., Klaunig, J., Meek, M. E., et al. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 35, 664-672.
63. Shu, H. P., Paustenbach, D. J., and Murray, F. J. (1987). A critical evaluation of the use of mutagenesis, carcinogenesis, and tumor promotion data in a cancer risk assessment of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Regul. Toxicol. Pharmacol. 7(1), 57-88.
64. Silkworth, J. B., Koganti, A., Illouz, K., Possolo, A., Zhao, M., and Hamilton, S. B. (2005). Comparison of TCDD and PCB CYP1A induction sensitivities in fresh hepatocytes from human donors, Sprague-Dawley rats, and rhesus monkeys and HepG2 cells. Toxicol. Sci. 87 (2), 508-519.
65. Slikker, W., Jr., Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., et al. (2004a). Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 201(3), 203-225.
66. Slikker, W., Jr., Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., et al. (2004b). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol. Appl. Pharmacol. 201(3), 226-294.
67. Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 34, 146-152.
68. Stinchcombe, S., Buchmann, A., Bock, K. W., and Schwarz, M. (1995). Inhibition of apoptosis during 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated tumour promotion in rat liver. Carcinogenesis 16(6), 1271-1275.
69. Teeguarden, J. G., Dragan, Y. P., Singh, J., Vaughan, J., Xu, Y. H., Goldsworthy, T., and Pitot, H. C. (1999). Quantitative analysis of dose- and time-dependent promotion of four phenotypes of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats. Toxicol. Sci. 51, 211-223.
70. ten Tusscher, G. W., Guchelaar, H. J., Koch, J., Ilsen, A., Vulsma, T., Westra, M., van der Slikke, J. W., Olie, K., and Koppe, J. G. (2008). Perinatal dioxin exposure, cytochrome P-450 activity, liver functions and thyroid hormones at follow-up after 7-12 years. Chemosphere 70(10), 1865-1872.
71. Tijet, N., Boutros, P. C., Moffat, I. D., Okey, A. B., Tuomisto, J., and Pohjanvirta, R. (2006). Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Mol. Pharmacol. 69(1), 140-153.
72. Toyoshiba, H., Walker, N. J., Bailer, A. J., and Portier, C. J. (2004). Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicol. Appl. Pharmacol. 194(2), 156-168.
73. Turteltaub, K. W., Felton, J. S., Gledhill, B. L., Vogel, J. S., Southon, J. R., Caffee, M. W., Finkel, R. C., Nelson, D. E., Proctor, I. D., and Davis, J. C. (1990). Accelerator mass spectrometry in biomedical dosimetry: Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl. Acad. Sci. U.S.A. 87(14), 5288-5292.
74. University of Michigan Dioxin Exposure Study (UMDES) (2006) Available at: http://www.sph.umich.edu/dioxin/index.html. Accessed January 23, 2008.
75. U.S. Environmental Protection Agency (USEPA). (1989). Interim Procedures for Estimating Risks Associated with Exposures to Mixtures of Chlorinated Dibenzo-p-Dioxins and -Dibenzofurans (CDDs and CDFs) and 1989 Update Risk Assessment Forum, Washington, DC. EPA/625/3-89.016.
76. USEPA. (2003). Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds NAS Review Draft. EPA/600/P-00/001Cb.
77. USEPA. (2005). Guidelines for Carcinogen Risk Assessment. EPA/630/ P-03/001F.
78. USEPA. (2006). Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment. EPA/600/R-05/043F August 2006. Available at: http://cfpub.epa.gov/ncea/CFM/nceaQFind.cfm?keyword=PBPK%20Models. Accessed January 23, 2008.
79. U.S. Environmental Protection Agency Science Advisory Board (USEPA SAB). (2001). Dioxin Reassessment-An SAB Review of the Office of Research and Development's Reassessment of Dioxin. Review of the Revised Sections (Dose Response Modeling, Integrated Summary, Risk Characterization, and Toxicity Equivalency Factors) of the EPA's Reassessment of Dioxin by the Dioxin Reassessment Review Subcommittee of the EPA Science Advisory Board (SAB) EPA-SAB-EC-01-006. Science Advisory Board, Washington, DC, May 2001 [online]. Available: http://www.epa.gov/ttn/atw/ ec01006.pdf. Accessed January 23, 2008.
80. Van den Berg, M., Birnbaum, L. S., Denison, M., De, V. M., Farland, W., Feeley, M., Fiedler, H., Hakansson, H., Hanberg, A., Haws, L., et al. (2006). The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol. Sci. 93, 223-241.
81. van Duursen, M. B., Sanderson, J. T., and Van den, B. M. (2005). Cytochrome P450 1A1 and 1B1 in human blood lymphocytes are not suitable as biomarkers of exposure to dioxin-like compounds: Polymorphisms and interindividual variation in expression and inducibility. Toxicol. Sci. 85(1), 703-712.
82. Viluksela, M., Bager, Y., Tuomisto, J. T., Scheu, G., Unkila, M., Pohjanvirta, R., Flodstrom, S., Kosma, V. M., Maki-Paakkanen, J., Vartiainen, T., et al. (2000). Liver tumor-promoting activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-sensitive and TCDD-resistant rat strains. Cancer Res. 60(24), 6911-6920.
83. Waern, F., Flodstrom, S., Busk, L., Kronevi, T., Nordgren, I., and Ahlborg, U. G. (1991). Relative liver tumour promoting activity and toxicity of some polychlorinated dibenzo-p-dioxin- and dibenzofuran-congeners in female Sprague-Dawley rats. Pharmacol. Toxicol. 69, 450-458.
84. Walker, N. J. (2007). Unraveling the complexities of the mechanism of action of dioxins. Toxicol. Sci. 95, 297-299.
85. Watson, M. A., Devereux, T. R., Malarkey, D. E., Anderson, M. W., and Maronpot,R.R. (1995). H-ras oncogene mutation spectra inB6C3F1andC57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis 16 (8), 1705-1710.
86. World Health Organization (WHO). (1998). Assessment of the health risk of dioxins: Re-evaluation of the Tolerable Daily Intake (TDI). WHO consultation, Geneva, Switzerland.
87. World Health Organization (WHO). (2000). Consultation on assessment of the health risk of dioxins; re-evaluation of the tolerable daily intake (TDI): Executive summary. Food Additiv. Contam. 17, 223-240.
88. Xu, L., Li, A. P., Kaminski, D. L., and Ruh, M. F. (2000). 2,3,7,8-Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. Chem. Biol. Interact. 124 (3), 173-189.